菲泽妥单抗 T77006
面议
- TargetMol
- 生产商
- 进口
- 美国
- 现货
- 全国
- 6
- 1
Product IntroductionBioactivity英文名: Felzartamab描述: Felzartamab(MOR-202) 是一种人源靶向 CD38 的单克隆抗体，可用于研究多发性骨髓瘤和晚期抗体介导的同种异体肾移植排斥反
AI问答
配套的仪器设备？
可以搭配的相关耗材试剂？
耗材描述
Product Introduction
Bioactivity
英文名: Felzartamab
描述: Felzartamab(MOR-202) 是一种人源靶向 CD38 的单克隆抗体，可用于研究多发性骨髓瘤和晚期抗体介导的同种异体肾移植排斥反应。
体外活性: MOR202-mediated toxic effects on multiple myeloma (MM) cell lines can be enhanced by the proteasome inhibitor bortezomib (BOR) and the immunomodulator lenalidomide (LEN).[1]
体内活性: MOR202 (12 mg/kg; murine MM models) dose-dependently reduced osteolysis by up to 55%. Coadministration with 0.6 mg/kg BOR or 50 mg/kg LEN completely eliminated osteolysis at a low dose of 3 mg/kg.[1]
存储条件: store at low temperaturestore at -20°C
关键字: MOR03087 | MOR202 | TJ 202 | Felzartamab | TJ202 | MOR 202 | MOR 03087
相关产品: CD38 inhibitor 1 | RBN013209 | CD38 inhibitor 3 | Erzotabart | Isatuximab | Luteolinidin chloride
Bioactivity
英文名: Felzartamab
描述: Felzartamab(MOR-202) 是一种人源靶向 CD38 的单克隆抗体，可用于研究多发性骨髓瘤和晚期抗体介导的同种异体肾移植排斥反应。
体外活性: MOR202-mediated toxic effects on multiple myeloma (MM) cell lines can be enhanced by the proteasome inhibitor bortezomib (BOR) and the immunomodulator lenalidomide (LEN).[1]
体内活性: MOR202 (12 mg/kg; murine MM models) dose-dependently reduced osteolysis by up to 55%. Coadministration with 0.6 mg/kg BOR or 50 mg/kg LEN completely eliminated osteolysis at a low dose of 3 mg/kg.[1]
存储条件: store at low temperaturestore at -20°C
关键字: MOR03087 | MOR202 | TJ 202 | Felzartamab | TJ202 | MOR 202 | MOR 03087
相关产品: CD38 inhibitor 1 | RBN013209 | CD38 inhibitor 3 | Erzotabart | Isatuximab | Luteolinidin chloride
猜你喜欢
感兴趣产品